Questions: Bacterial Toxins and Virulence Mechanisms

Question 1

Cholera toxin's A subunit permanently activates adenylyl cyclase in intestinal epithelial cells through ADP-ribosylation. Even if all Vibrio cholerae bacteria are killed with antibiotics at this point, severe secretory diarrhea continues. Why?

• A. The dying bacteria release additional toxin as they lyse, amplifying the effect
• B. Antibiotics cannot penetrate the intestinal lumen where cholera toxin acts
• C. The covalent enzymatic modification is already done — adenylyl cyclase remains locked in an active state until the cell synthesizes new, unmodified regulatory protein
• D. Cholera toxin has a half-life of several days in intestinal tissue and continues acting long after bacteria are cleared

Answer: (C)

The A subunit of cholera toxin ADP-ribosylates the Gs regulatory protein, a covalent and irreversible modification that locks adenylyl cyclase in an active state. Killing the bacteria does not reverse this modification. The intestinal cell continues secreting chloride and water until it synthesizes new, unmodified protein. This illustrates a key feature of enzymatic exotoxins: their catalytic nature produces sustained, amplified damage that outlasts the toxin's own presence — and the bacteria that made it.

Question 2

The diphtheria vaccine uses a toxoid — chemically inactivated diphtheria toxin that cannot cause disease but remains immunogenic. Why does this vaccination protect against diphtheria even though it does not kill Corynebacterium diphtheriae?

• A. Toxoid-induced antibodies also bind the bacterial cell surface, preventing colonization of the throat
• B. Toxoid-induced antibodies neutralize the toxin before it can damage cells, so bacteria can colonize but cannot cause disease
• C. The vaccine stimulates cytotoxic T cells that recognize and eliminate bacteria producing the toxin
• D. Toxoid vaccines provide only short-term protection and must be combined with antibiotics for complete coverage

Answer: (B)

For toxigenic diseases like diphtheria, pathology is caused by the toxin, not the bacterium itself. Antibodies raised against the toxoid recognize and neutralize the toxin — blocking its binding to cell receptors or preventing cellular entry — even if bacteria successfully colonize the throat. The bacteria may persist, but without functional toxin reaching target cells, no disease occurs. This reveals that treating or preventing toxigenic infections can target the toxin rather than the organism.

Question 3

Superantigens like staphylococcal TSST-1 can activate up to 20% of all T cells simultaneously, compared to the fraction of a percent activated by a conventional antigen.

• T. True
• F. False

Answer: True

Conventional antigen presentation selects for T cells whose TCR specifically matches the processed peptide–MHC complex — typically 1 in 10,000 T cells. Superantigens bypass this specificity by crosslinking MHC class II molecules directly to the Vβ domain of TCRs, which is shared by large families of T cells regardless of antigen specificity. Any given Vβ family represents up to 20% of T cells, so superantigens trigger massive simultaneous T cell activation, releasing a cytokine storm that produces toxic shock syndrome.

Question 4

Endotoxin is a protein secreted by gram-negative bacteria that directly damages host cells through enzymatic activity.

• T. True
• F. False

Answer: False

Endotoxin (lipopolysaccharide, LPS) is not a secreted protein — it is a structural component of the gram-negative outer membrane, released when bacteria die and lyse. Unlike exotoxins (which are proteins actively secreted with specific enzymatic or receptor-binding activities), LPS triggers harm indirectly by activating the innate immune system through TLR4 on macrophages, causing systemic inflammatory responses. In large quantities, this immune activation produces septic shock — not direct cellular damage by the LPS molecule itself.

Question 5

Explain why antitoxin treatment can be effective for botulism and diphtheria even after infection is well established, and what this reveals about the nature of these diseases.

Model answer: In toxigenic diseases, pathology is caused by the toxin, not the bacterium itself. Antibodies (antitoxin) can neutralize toxin molecules that are still circulating in the bloodstream or not yet internalized into target cells, preventing further damage — even after bacterial infection is established. Antibiotics can clear the bacteria but cannot reverse toxin already bound or active inside cells; antitoxin intercepts accessible extracellular toxin. This reveals that for many toxigenic infections, the disease process is driven by the toxin acting at a distance from the bacteria, making toxin neutralization a primary therapeutic target. It also explains why toxoid vaccines are so effective: they prime immunity against the disease-causing molecule rather than just the organism.

The clinical implication is significant: in botulism, for example, antitoxin must be administered promptly — before toxin is internalized at neuromuscular junctions. Once botulinum toxin has cleaved SNARE proteins inside the nerve terminal, antitoxin cannot reverse the existing paralysis (only prevent further toxin from acting). This is why early diagnosis and treatment matters in toxigenic diseases, and why understanding the mechanism of toxin action is directly clinically relevant.